Related Experiment Video
Updated: Jun 17, 2026
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer
Takehiko Okamura1, Kouji Izumi2, Satoshi Kurokawa1
1Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.
Background:
Clinical trials rarely focus on elder patients with castration-resistant prostate cancer (CRPC), and data on the outcomes of second-generation androgen receptor signaling inhibitors (ARSIs) remain limited.
Methods:
The ENABLE study for prostate cancer was an investigator-initiated, multicenter, randomized controlled trial conducted in Japan to compare enzalutamide (ENZ) and abiraterone plus prednisolone (ABI). This sub-analysis was performed to evaluate the efficacy and the safety profiles between patients aged ≥ 75 (older) and < 75 years (younger), and then between the ENZ and ABI arms in the older and the younger cohort separately.
Results:
The ENZ arm included 41 younger and 51 older patients, while the ABI arm included 36 younger and 56 older patients. No significant differences in survival endpoints were observed between younger and older patients. Median time to prostate-specific antigen (PSA) progression (TTPP) was 15.2 months for younger and 21.2 months for older patients (HR 0.84, 95% CI 0.53-1.33, p = 0.4647). Median overall survival (OS) was 33.7 months for younger and 37.8 months for older patients (HR 0.80, 95% CI 0.50-1.29, p = 0.3651). Among older patients (n = 107), the ENZ arm had a TTPP of 21.2 months compared to 10.1 months for the ABI arm and an OS of 37.8 months compared to 44.7 months for the ABI arm (p = 0.1506 and p = 0.9321, respectively). Any grade and grade ≥ 3 adverse events were observed in 47 (61%) and 11 (14%) younger patients and 73 (68%) and 18 (17%) older patients, respectively. No significant differences were found in any grade or grade ≥ 3 adverse events between younger and older patients (p = 0.3487 and p = 0.6885, respectively).
Conclusions:
ARSIs demonstrated similar efficacy and safety in both younger and older patients. ENZ may be a more suitable option for older patients due to its higher PSA response rate.
Clinical Trial Registration:
This trial was registered with the University Hospital Medical Information Network (UMIN) Center under identifier UMIN000015529.
Insights
Second-generation androgen receptor signaling inhibitors (ARSIs) show similar efficacy and safety in older and younger patients with castration-resistant prostate cancer. Enzalutamide may be a better choice for elderly individuals.
Area of Science:
- Oncology
- Urology
- Clinical Pharmacology
Background:
- Limited clinical trial data exists for elderly patients with castration-resistant prostate cancer (CRPC).
- Outcomes of second-generation androgen receptor signaling inhibitors (ARSIs) in older CRPC patients are not well-documented.
Purpose of the Study:
- To compare the efficacy and safety of enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) in older versus younger patients with CRPC.
- To analyze treatment outcomes within older and younger cohorts separately for ENZ and ABI.
Main Methods:
- Sub-analysis of the multicenter, randomized controlled ENABLE study conducted in Japan.
- Patients were stratified into two groups: aged ≥75 years (older) and <75 years (younger).
- Efficacy endpoints included time to prostate-specific antigen (PSA) progression (TTPP) and overall survival (OS); safety was assessed via adverse events.
Main Results:
- No significant differences in survival endpoints (TTPP, OS) were observed between younger and older patients.
- Among older patients, enzalutamide showed a trend towards longer TTPP (21.2 vs. 10.1 months) and OS (37.8 vs. 44.7 months) compared to abiraterone, though not statistically significant.
- Adverse event rates were similar between younger and older patients, and between treatment arms.
Conclusions:
- Androgen receptor signaling inhibitors (ARSIs) exhibit comparable efficacy and safety profiles in both younger and older patients with CRPC.
- Enzalutamide (ENZ) may represent a more favorable treatment option for elderly CRPC patients, potentially due to higher PSA response rates.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment